DCTs in Oncology: Can They Work?

The FDA’s 2024 guidance on decentralized clinical trials (DCTs) has the potential to transform clinical research, particularly in oncology. While many still view DCTs as either fully virtual or fully in-person, the guidance promotes a hybrid approach, blending traditional and decentralized elements. This flexibility may help smaller sites participate alongside large academic medical centers, making trials more accessible to rural and underserved areas.However, challenges remain, including reg...